Writing
Writing from clinic
and research
Notes on what the literature actually changes in practice, how we structure multimodal care, and what trial data does and does not say. Teaching cases will be de-identified.
What’s New in Mild Cognitive Impairment
The papers that changed how we practice: where anti-amyloid antibodies are narrowing rather than broadening; metabolism as a front door; exercise data that holds up; inflammation; hormones and timing; and AI that is finally usable in memory care.
Read the series →Precision Medicine: The Rezilir Approach
Precision medicine as practice, not a supplement plan. Individual biomarkers, interventions sequenced by judgment, outcomes named in advance, and a six-month window where change should be measurable.
Read essay →Evanthea Trial: Future of Alzheimer’s Care
What the multicenter randomized trial of personalized precision medicine for MCI and early dementia tested. Rezilir was a PI site in Hollywood. Preprint results and what they mean for care design.
Read explainer →Anti-Amyloid Antibodies Are Narrowing, Not Broadening
Where monoclonal antibodies fit, and where they do not, next to precision approaches that address root drivers first.
Read part 1 →